Platzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L., Noppeney, R., Bug, G., Götze, K. S., Krämer, A., Bochtler, T., Stelljes, M., Groth, C., Schubert, A., Mende, M., Stölzel, F., Borkmann, C., Kubasch, A. S., von Bonin, M., Serve, H., Hänel, M., Dührsen, U., Schetelig, J., Röllig, C., Kramer, M., Ehninger, G., Bornhäuser, M., & Thiede, C. (2018). measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet oncology, 19(12), 1668–1679. http://access.bl.uk/ark:/81055/vdc_100073670405.0x00001d